Literature DB >> 23312056

Glycogen storage disease type Ia: linkage of glucose, glycogen, lactic acid, triglyceride, and uric acid metabolism.

Sakine Sever1, David A Weinstein, Joseph I Wolfsdorf, Reyhan Gedik, Ernst J Schaefer.   

Abstract

A female presented in infancy with hypotonia, undetectable serum glucose, lactic acidosis, and triglycerides >5000 mg/dL. The diagnosis of type 1A glycogen storage disease was made via the result of a liver biopsy, which showed increased glycogen and absent glucose-6-phosphatase enzyme activity. The patient was treated with dextrose administered orally, which was replaced by frequent feedings of cornstarch, which resulted in an improvement of her metabolic parameters. At age 18 years of age, she had marked hypertriglyceridemia (3860 mg/dL) and eruptive xanthomas and was treated with fenofibrate, atorvastatin, and fish oil. At age 29 years she was noted to have multiple liver adenomas, severe anemia, and hyperuricemia. Aggressive cornstarch therapy was commenced with a goal of maintaining her blood glucose levels >75 mg/dL and lactate levels <2 mmol/L. After 15 months on this regimen, her lipids levels (measured in mg/dL) off all medications were as follows: total cholesterol 222, triglycerides 179, high-density lipoprotein cholesterol 32, and calculated low-density lipoprotein cholesterol 154. Her weight was stable with a body mass index of 24.8 kg/m(2). Her liver adenomas had decreased in size, and her anemia and hyperuricemia had improved. She was homozygous for the R83C missense mutation in G6PC. Our data indicate that optimized metabolic control to maintain blood glucose levels >75 mg/dL is critical in the management of this disease.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23312056      PMCID: PMC3812663          DOI: 10.1016/j.jacl.2012.08.005

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  17 in total

Review 1.  Molecular genetics of type 1 glycogen storage disease.

Authors:  A R Janecke; E Mayatepek; G Utermann
Journal:  Mol Genet Metab       Date:  2001-06       Impact factor: 4.797

Review 2.  Glycogen storage diseases.

Authors:  Joseph I Wolfsdorf; David A Weinstein
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

3.  High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study.

Authors:  Bela F Asztalos; L Adrienne Cupples; Serkalem Demissie; Katalin V Horvath; Caitlin E Cox; Marcelo C Batista; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-23       Impact factor: 8.311

4.  Hepcidin and the anemia of chronic disease.

Authors:  Farid I Haurani
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

Review 5.  Hepcidin and anaemia.

Authors:  Robert T Means
Journal:  Blood Rev       Date:  2004-12       Impact factor: 8.250

6.  Severe iron deficiency anemia in transgenic mice expressing liver hepcidin.

Authors:  Gaël Nicolas; Myriam Bennoun; Arlette Porteu; Sandrine Mativet; Carole Beaumont; Bernard Grandchamp; Mario Sirito; Michèle Sawadogo; Axel Kahn; Sophie Vaulont
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

7.  Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a.

Authors:  Robert H J Bandsma; Berthil H Prinsen; Monique de Sain van Der Velden; Jan-Peter Rake; Theo Boer; G Peter A Smit; Dirk-Jan Reijngoud; Folkert Kuipers
Journal:  Pediatr Res       Date:  2008-06       Impact factor: 3.756

8.  Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.

Authors:  Erik Ingelsson; Ernst J Schaefer; John H Contois; Judith R McNamara; Lisa Sullivan; Michelle J Keyes; Michael J Pencina; Christopher Schoonmaker; Peter W F Wilson; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

9.  Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.

Authors:  David A Weinstein; Cindy N Roy; Mark D Fleming; Massimo F Loda; Joseph I Wolfsdorf; Nancy C Andrews
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

10.  Structure-function analysis of human glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1a.

Authors:  K J Lei; C J Pan; J L Liu; L L Shelly; J Y Chou
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

View more
  5 in total

Review 1.  Hepatic glucose sensing and integrative pathways in the liver.

Authors:  Maaike H Oosterveer; Kristina Schoonjans
Journal:  Cell Mol Life Sci       Date:  2013-11-07       Impact factor: 9.261

2.  Crystal structure of lipid phosphatase Escherichia coli phosphatidylglycerophosphate phosphatase B.

Authors:  Junping Fan; Daohua Jiang; Yan Zhao; Jianfeng Liu; Xuejun Cai Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

Review 3.  Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases.

Authors:  Zeljka Trepotec; Eva Lichtenegger; Christian Plank; Manish K Aneja; Carsten Rudolph
Journal:  Mol Ther       Date:  2018-12-22       Impact factor: 11.454

4.  A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.

Authors:  Jin Zhou; Lauren R Waskowicz; Andrea Lim; Xiao-Hui Liao; Brian Lian; Hiroko Masamune; Samuel Refetoff; Brian Tran; Dwight D Koeberl; Paul M Yen
Journal:  Thyroid       Date:  2019-08       Impact factor: 6.568

5.  Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.

Authors:  Elizabeth D Brooks; Dustin J Landau; Jeffrey I Everitt; Talmage T Brown; Kylie M Grady; Lauren Waskowicz; Cameron R Bass; John D'Angelo; Yohannes G Asfaw; Kyha Williams; Priya S Kishnani; Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2018-07-24       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.